For nicotine addiction, which pharmacotherapy is considered first-line?

• A. Varenicline
• B. Bupropion
• C. Nicotine replacement therapy
• D. Clonidine

Answer: (A)

Varenicline is considered first-line because it directly targets the nicotine addiction pathway by acting as a partial agonist at alpha4beta2 nicotinic receptors. This dual action both eases withdrawal symptoms through baseline receptor stimulation and blocks nicotine’s rewarding effects if a person smokes while taking it. In clinical trials, it tends to produce higher abstinence rates at follow-ups like 6–12 months compared with placebo and often outperforms other pharmacotherapies such as nicotine replacement therapy or bupropion. That robust efficacy underpins its placement as a preferred first-line option.

Common side effects include nausea and sleep disturbances, and while there have been concerns about mood changes, varenicline remains a leading choice for many patients due to its strong quit-rate data. Nicotine replacement therapy and bupropion are also effective first-line options, but varenicline’s demonstrated superiority in abstinence outcomes explains why it’s highlighted as the top choice. Clonidine does not have the same level of evidence for smoking cessation and is not considered first-line.